MMF After Pediatric Liver Transplantation

Hannover Medical School (MHH)

Status: Completed

Conditions: Chronic Kidney Disease; Liver Transplantation

Treatments: Drug: MMF

Study type: Interventional

Funder types: Other

Identifiers

NCT00367146

MHH3474MMF

Details and patient eligibility

About

The use of CNIs (CSA or FK) as primary immunosuppressive drugs after pediatric liver transplantation is one of the main causes of chronic kidney disease in these patients in the long term.

The study objective is the evaluation of safety of a modification in immunosuppression from a dual-immunosuppression (CSA or FK plus steroids) to a triple immunosuppression (MMF plus CSA (reduced dosage) plus steroids.

Enrollment: 25 patients

Sex: All

Ages: Under 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients after pediatric liver transplantation
• no acute rejections for the last half year

Exclusion criteria

• concomitant malign disease (e.g. ptld)
• neutropenia (granulocytes <1000/µl)
• systemic infection
• thrombopenia (<80/nl)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)